Solutions to such problems were chiefly seen to lie at the international level. In particular, respondents called for improved collaboration between Finnish national authorities and the European Medicines Agency (EMA), particularly around regulation of new diagnostics, and through involvement in the EMA Innovative Medicines Task Force. Two respondents mentioned intellectual property issues as important, with one calling for the maintenance of a strong European patent regime, and another for more complementary and parallel IP systems between countries and continents. Another suggested that common international legislation on biobanking would help to facilitate developments in Finland.